Is MBX Worth Buying in 2026?

MBX Biosciences, Inc. Common Stock

STOCK PHARMACEUTICAL PREPARATIONS Updated 2026-06-14

Here’s whether MBX Biosciences, Inc. Common Stock (MBX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.

🟢
Bullish

Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+1.72% over 10 days); RSI 62 — healthy momentum range; strong 1-year return of +231.2%; 3-month momentum positive (+19.2%); rising volume confirms the move (1.17x 30d avg). Currently 22.6% off its 52-week high. Score: +8/7.

Ready to act on this? 📈 Trade on Webull

MBX is in a confirmed uptrend, trading above both its 50-day ($32.38) and 200-day ($28.05) moving averages. An RSI of 62.2 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +231.3% compares to +22.9% for SPY (beat the market by 208.4%). The current 22.6% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.

$10,000 invested 1 year ago → $33,125 today
vs. S&P 500 (SPY) — same period beat market by 208.4%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

Above 200-day MA ($28.05)
Above 50-day MA ($32.38)
RSI(14) neutral zone (30–70) — currently 62.2
Positive return (+231.3%)
!Within 10% of period high (−22.6%)
Period Range $35.51
$9.43 $45.85
RSI (14) 62.2
0 · OversoldOverbought · 100

Key Metrics

Price$35.51
Period Return+231.3%
Period High$45.85
Period Low$9.43
Drawdown−22.6%
MA-50$32.38
MA-200$28.05
RSI (14)62.2
Avg Volume (30d)808K
vs. SPYbeat by 208.4%
Return Rank#88 of 1246

Trade MBX

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers